SCHEMBL6899085

SCHEMBL6899085

CC(C)(CCc1cc(=O)c(O)co1)CC[S+]([O-])CC[S+]([O-])CCC(C)(C)CCc1cocc(O)c1=O

nearest known ligand 0.37

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
TYR P14679 8/20 0.37
DAO P14920 3/20 0.37
KDM4E B2RXH2 1/20 0.37
IDH1 O75874 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6533157 0.89 TYR (0.46) TYRDAOKDM4EIDH1
SCHEMBL6707590 0.88
SCHEMBL6708527 0.87 TYR (0.39) TYRDAOKDM4EIDH1
SCHEMBL6506819 0.83 TYR (0.37) TYRDAOKDM4E
SCHEMBL3279828 0.83 TYR (0.39) TYRDAOKDM4EIDH1
SCHEMBL13053752 0.83 TYR (0.39) TYRDAOKDM4EIDH1
SCHEMBL7177364 0.83
SCHEMBL6345629 0.82 TYR (0.38) TYRDAOKDM4EIDH1
SCHEMBL6345631 0.81 DAO (0.39) TYRDAOKDM4EIDH1
SCHEMBL6702707 0.81 TYR (0.47) TYRDAOKDM4EIDH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6673780-B2 SUCH AS 4-(4-(3-HYDROXY-3-METHYL-BUTANE-1-SULFINYLMETHYL)-PHENYLMETHANESULFINYL)-2 -METHYL-BUTAN1-OL FOR TREATING AND PREVENTING CARDIOVASCULAR DISEASES, DYSLIPIDEMIAS, DYSPROTEINEMIAS, AND GLUCOSE METABOLISM DISORDERS ESPERION THERAPEUTICS, INC. 2004-01-06 US claimed
EP-1366024-A2 SULFOXIDE AND BIS-SULFOXIDE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES Esperion Therapeutics Inc. (US) 2003-12-03 EP disclosed
WO-2002030882-A2 SULFOXIDE AND BIS-SULFOXIDE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES ESPERION THERAPEUTICS, INC. (US) 2002-04-18 WO disclosed